Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42066 | 0.84 | HRH1 (0.62) | KDM4EL3MBTL1AOC3HRH1HTR2A | |
| SCHEMBL3179795 | 0.84 | HRH1 (0.62) | KDM4EL3MBTL1AOC3HRH1HTR2A | |
| SCHEMBL232834 | 0.84 | HRH1 (0.62) | KDM4EL3MBTL1AOC3HRH1HTR2A | |
| SCHEMBL21896763 | 0.84 | KDM4E (0.66) | KDM4EL3MBTL1AOC3LMNABCAT2 | |
| SCHEMBL11381473 | 0.84 | KDM4E (0.66) | KDM4EL3MBTL1AOC3LMNABCAT2 | |
| SCHEMBL2185597 | 0.83 | KDM4E (0.70) | KDM4EL3MBTL1AOC3LMNABCAT2 | |
| SCHEMBL7356714 | 0.83 | KDM4E (0.53) | KDM4EL3MBTL1AOC3KCNH2RIPK1 | |
| SCHEMBL4204090 | 0.82 | KCNH2 (0.65) | HRH1HTR2AKCNH2LMNAALDH1A1 | |
| SCHEMBL5093350 | 0.82 | MEN1 (0.48) | KDM4EAOC3SIGMAR1 | |
| SCHEMBL9191899 | 0.82 | ALDH1A1 (0.55) | KDM4EL3MBTL1KCNH2RIPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449477-B2 | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | ELI LILLY AND COMPANY | 2007-02-15 | — | — | US | disclosed |
| EP-1689719-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054202-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | POLI, HRAS, CHUK | KDM4E 2390/4885L3MBTL1 3340/4885AOC3 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.